Chemical Compound

Monomethyl auristatin E

CAS Registry Number 474645-27-7
Back to search Request a Quote
Monomethyl auristatin E chemical structure
Primary Record

Monomethyl auristatin E

In stock
3,997 g
Purity
99.0 %
CAS
474645-27-7

Compound Identifiers & Properties

CAS
474645-27-7
PubChem CID
11542188
SMILES
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC
Canonical SMILES
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@@H](NC)C(C)C)C(C)C

Names & Synonyms

  • Monomethyl auristatin E
  • MMAE
  • Monomethylauristatin E
  • MMAE peptide
  • 474645-27-7
  • VEDOTIN
  • Vedotin [USAN]
  • [3H]-Vedotin
  • V7I58RC5EJ
  • UNII-V7I58RC5EJ
  • Anti-CD79b-vc-vedotin
  • Anti-CD79b-vc-MMAE
  • RefChem:159590
  • Anti-CD79b-MC-MMAF
  • MMAE (Monomethyl auristatin E)
  • Anti-CD79b-MCC-DM1
  • D0M7EP
  • CD79-targeted immunotoxins
  • Monomethyl auristatin E (GMP)
  • UNII-Q3606FDE0B
  • MFCD22124498
  • SGD-1010
  • MMAE, monomethyl auristatin E
  • DASWEROEPLKSEI-UIJRFTGLSA-N
  • C39H67N5O7
  • DTXSID101028844
  • SCHEMBL5402144
  • CHEMBL2103835
  • Monomethyl auristatin E (MMAE)
  • AMY9235
  • AOB5196
  • DTXCID801514480
  • GLXC-06285
  • Monomethyl auristatin E (Standard)
  • MONOMETHYLAURISTATIN E [MI]
  • Monomethyl auristatin E (vedotin)?
  • BBF-05782
  • FD9056
  • HY-15162G
  • HY-15162R
  • MSK169050
  • NSC791792
  • NSC832263
  • s7721
  • ZINC85537145
  • AKOS025312191
  • CCG-270400
  • CS-0837
  • FM63498
  • NSC-791792
  • NSC-832263
  • CID11542188
  • MonoMethyl auristatin E(MMAE, vedotin)
  • BP-22278
  • CID 11542188
  • CID:11542188
  • HY-15162
  • SY034481
  • SID:448284048
  • AB0087989
  • CS-0899132
  • Y1831
  • J1.915.648F
  • A12954
  • W-5883
  • A852551
  • C495575
  • CD79-targeted immunotoxins (non-Hodgkin's lymphoma)
  • Q6901739
  • (2S)-N-[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide
  • (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-Hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide
  • N-Methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide
  • CD79-targeted immunotoxins (non-Hodgkin's lymphoma), Genentech
  • N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
  • (2S)-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-2-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]carbamoyl}-1-methoxy-2-methylethyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N,3-dimethyl-2-[(2S)-3-methyl-2-(methylamino)butanamido]butanamide
  • Anti-CD79 antibody-drug conjugates (non-Hodgkin's lymphoma), Genentech
  • (2R,3R)-N-[(1R,2S)-1-Methyl-2-hydroxy-2-phenylethyl]-2-methyl-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-4-[(N-methyl-L-Val-L-Val-)(methyl)amino]-5-methylheptanoyl]-2-pyrrolidinyl]-3-methoxypropanamide
  • (2R,3R)-N-[(alphaR,betaS)-alpha-Methyl-beta-hydroxyphenethyl]-2-methyl-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-4-[methyl(N-methyl-Val-Val-)amino]-5-methylheptanoyl]pyrrolidine-2-yl]-3-methoxypropionamide
  • (2S)-N-[(1S)-1-[[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl]amino]-1-methoxy-2-methyl-3-oxo-propyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxo-butyl]-methyl-carbamoyl]-2-methyl-propyl]-3-methyl-2-(methylamino)butanamide
  • (S)-2-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-N-(methyl-L-valyl)butanamide
  • (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1R,2R)-1-Hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxohe
  • 4Q5
  • L-Valinamide, N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1- methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-2- methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-
  • L-Valinamide, N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-
  • N(sup 2)-(N-Methyl-L-valyl)-N(sup 1)-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-methyl-2- phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)- 1-methylpropyl)-4-oxobutyl)-N(sup 1)-methyl-L-valinamide
  • N(sup 2)-(N-methyl-L-valyl)-N(sup 1)-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N(sup 1)-methyl-L-valinamide
  • n-methyl-l-valyl-n-[(1s,2r)-4-[(2s)-2-[(1r,2r)-3-[[(1r,2s)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-n-methyl-l-valinamide
  • N-Methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide; MMAE; Monomethylauristatin E; Monomethylauristatin Norephedrine;